During the analysts call today the CFO confirmed that there would be minimal R&D expenditure this year. During FY'23 R&D was $7.5m so it is fair to assume this will add to the EBITDA result and about $5m additional to flow to NPAT.
The business is also very confident of another year of increasing cash generation, particularly in H2 which is the normal seasonal split of cash generation.
Cheers.....D
During the analysts call today the CFO confirmed that there...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IRI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
-0.015(1.60%) |
Mkt cap ! $161.5M | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 97.0¢ | 91.0¢ | $282.2K | 297.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 499 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.5¢ | 527 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| IRI (ASX) Chart |